CATALOGO DEI PRODOTTI DELLA RICERCA

QUAGLIA, Francesca Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.496
NA - Nord America 1.313
AS - Asia 1.298
SA - Sud America 217
AF - Africa 122
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.462
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.667
US - Stati Uniti d'America 1.220
SG - Singapore 578
IT - Italia 254
CN - Cina 235
VN - Vietnam 156
BR - Brasile 146
HK - Hong Kong 132
GB - Regno Unito 128
BJ - Benin 87
DE - Germania 81
FR - Francia 64
SE - Svezia 53
IN - India 48
MX - Messico 48
NL - Olanda 48
IE - Irlanda 38
ES - Italia 37
CA - Canada 35
FI - Finlandia 27
PL - Polonia 27
AR - Argentina 26
ID - Indonesia 23
AT - Austria 21
JP - Giappone 21
KR - Corea 20
TR - Turchia 16
ZA - Sudafrica 16
EC - Ecuador 15
AU - Australia 12
RO - Romania 11
BD - Bangladesh 9
IQ - Iraq 8
VE - Venezuela 8
CO - Colombia 7
IL - Israele 7
UA - Ucraina 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
HN - Honduras 6
LT - Lituania 6
BE - Belgio 5
PK - Pakistan 5
PY - Paraguay 5
CL - Cile 4
PH - Filippine 4
QA - Qatar 4
SA - Arabia Saudita 4
TG - Togo 4
BG - Bulgaria 3
IR - Iran 3
MA - Marocco 3
PE - Perù 3
PT - Portogallo 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
CG - Congo 2
EG - Egitto 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GY - Guiana 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
MD - Moldavia 1
MU - Mauritius 1
MY - Malesia 1
NC - Nuova Caledonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 5.462
Salva come PNG Salva come JPEG
Città #
Moscow 716
Singapore 340
Ashburn 223
Dallas 160
Hong Kong 130
Chandler 96
Cotonou 87
Los Angeles 64
Beijing 63
New York 56
Verona 50
Ho Chi Minh City 49
Dublin 38
Hanoi 38
Buffalo 36
Milan 34
London 30
Orem 27
Mexico City 25
São Paulo 23
Warsaw 23
Xi'an 23
Denver 22
Munich 21
Montreal 20
Brooklyn 19
Stockholm 18
Atlanta 17
Chennai 17
Houston 16
Poplar 16
Tokyo 16
Johannesburg 14
Querétaro 14
Santa Clara 14
Southend 14
Jacksonville 13
Seattle 12
Falkenstein 11
Helsinki 11
Manchester 11
Phoenix 11
The Dalles 11
Bologna 10
Boston 10
Bucharest 10
Jakarta 10
Lawrence 10
Melbourne 10
Princeton 10
Wilmington 10
Amsterdam 9
Mumbai 9
Vienna 9
Ankara 8
Boardman 8
Council Bluffs 8
Da Nang 8
Dong Ket 8
Jinan 8
Lappeenranta 8
Redondo Beach 8
Tianjin 8
Columbus 7
Haiphong 7
Hürth 7
Madrid 7
Chicago 6
Frankfurt am Main 6
Guayaquil 6
New Delhi 6
Ninh Bình 6
Nuremberg 6
Toronto 6
Brussels 5
Padua 5
Raleigh 5
Seoul 5
Sindelfingen 5
Tegucigalpa 5
Turku 5
Bogotá 4
Brookline 4
Cagliari 4
Campinas 4
Curitiba 4
Doha 4
Genoa 4
Guangzhou 4
Haikou 4
Kingsland 4
Lomé 4
Miami 4
Naples 4
Norwalk 4
Porto Alegre 4
Quito 4
Sargodha 4
Shijiazhuang 4
Terrassa 4
Totale 3.009
Salva come PNG Salva come JPEG
Nome #
Fentanyl buccal tablet: a new breakthrough pain medication in early management of severe vaso-occlusive crisis in sickle cell disease. 184
Chronic lymphocytic leukemia and mantle cell lymphoma: similarities and differences from an integrated biological and clinical approach 183
The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia 169
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 164
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 152
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 150
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 141
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 140
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 140
Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease 137
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 131
Bendamustine plus rituximab: is it a BRIGHT idea? 125
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 119
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 116
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 103
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 95
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 91
Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin's Lymphoma: A Case Report and Review of the Literature 80
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 65
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 65
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 62
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 58
SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE 54
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations 54
THE ROLE OF STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 54
FITNESS STATUS AND TIME TO FIRST PROGRESSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE “ELDERLY MANTLE-FIRST” STUDY 46
Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. 45
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 45
B-CELL RECEPTOR SIGNALING ACTIVITY IDENTIFIES PATIENTS WITH MANTLE CELL LYMPHOMA AT HIGHER RISK OF PROGRESSION 45
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 44
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920) 44
GENETIC AND EPIGENETIC MECHANISMS REGULATING CATALASE EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA 44
A MULTI‐CENTER REAL‐LIFE ANALYSIS ON PATIENTS WITH LARGE B‐CELL LYMPHOMA AFTER FAILURE OF CAR‐T CELLS THERAPY 43
A phospho-specific flow cytometry study reveals the impact of BCR signaling activation in mantle cell lymphoma progression and therapy 43
ACTIVATION OF BCR SIGNALING REWIRES THE RESPONSE OF BCR-ASSOCIATED KINASES TO IBRUTINIB IN MANTLE CELL LYMPHOMA CELLS 43
Callosal agenesis in craniofrontonasal dysplasia 42
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 41
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report 41
B-CELL RECEPTOR SIGNALING PROFILES IN MANTLE CELL LYMPHOMA: A BARCODING AND PHOSPHO-SPECIFIC FLOW CYTOMETRY APPROACH 41
THE PROGNOSTIC ROLE OF DEL 9P21.3 (CDKN2A) IN PATIENTS WITH MANTLE CELL LYMPHOMA. RESULTS FROM THE FIL_MANTLE-FIRST BIO STUDY 40
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 40
B-CELL RECEPTOR SIGNALING PROFILES IDENTIFY SUBSETS OF MANTLE CELL LYMPHOMA PATIENTS WITH DIFFERENT CLINICAL OUTCOMES 39
OUTCOME OF 100 TP53-DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED FRONT-LINE WITH IBRUTINIB. A REAL-LIFE CAMPUS CLL STUDY. 39
ARGO, AUTOMATIC RECORD GENERATOR IN ONCOLOGY: MULTICENTRIC VALIDATION OF A NEW TOOL FOR AUTO- MATIC CONVERSION OF “REAL-LIFE” HEMOLYMPHOPATHOL- OGY REPORTS IN STANDARDIZED ECRF 38
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 38
IN CHRONIC LYMPHOCYTIC LEUKAEMIA WITH COMPLEX KARYOTYPE, MAJOR STRUCTURAL ABNORMALITIES IDENTI- FY A SUBSET OF PATIENTS WITH INFERIOR OUTCOME AND DISTINCT BIOLOGIC CHARACTERISTICS 38
BCR signaling activity stratifies patents with MCL with divergent clinical outcome 37
R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy 37
Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus 37
Atherosclerotic ectasia of coronary arteries 37
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 36
RESPONSE TO IBRUTINIB OF AN AGGRESSIVE IG-A LYMPHOPLASMACYTIC LYMPHOMA CARRYING THE MYD88 L265P GENE MUTATION 36
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study 35
Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs 35
AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS 35
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 35
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study 35
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 34
Paraaortic PEComa 34
Regulation of catalase gene expression in chronic lymphocytic leukemia patients. 34
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 34
THE PROGNOSTIC SIGNIFICANCE OF MYC AND BCL2 PROTEIN DOUBLE EXPRESSION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, NOS, IN THE ABSENCE OF MYC REARRANGEMENT 34
Association of genetic polymorphisms with differential catalase gene expression in prognostic groups of chronic lymphocytic leukemia patients. 33
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study 33
Brachial aneurysm following arterovenous fistula ligation 33
Cavernous sinus thrombosis: exophtalmos in a patient with Internal Carotid Artery (ICA) aneurysm 32
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL‐LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 32
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: results from the ELDERLY MANTLE-FIRST study 32
Fluorescent cell barcoding and phospho-specific flow cytometry characterize B-cell receptor signaling profiles associated with different clinical outcome in mantle cell lymphoma 32
Recurrent infiltrative cancer of the cheek: a case report 31
Diagnosis of groove pancreatitis in patient with chronic pancreatitis and recurrent abdominal pain 31
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 31
Different infiltration patterns within the tumor microenvironment can identify mantle cell lymphoma patients with different clinical outcomes. Results from a pilot clinical-pathological study 31
Gastroepiploic artery bypass graft 31
Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 31
Left main coronary artery aneurysm 30
Simultaneous abdominal histoplasmosis and cerebral toxoplasmosis in an AIDS patient 30
PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF THE B-CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA 30
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion 29
Ultrasound guided radiofrequency thermoablation of thyroid substernal goiter 29
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 29
HBV REACTIVATION IN CLL PATIENTS WITH OCCULT HBV INFECTION TREATED WITH IBRUTINIB WITH OR WITHOUT VIRAL PROPHYLAXIS. A RETROSPECTIVE MULTICENTRIC GIMEMA STUDY 29
CATALASE EXPRESSION IN LEUKEMIA CELLS IS CONTROLLED BY GENETIC AND EPIGENETIC MECHANISMS 29
Worldwide Examination of Patients with CLL Hospitalized for COVID-19 29
Notch signaling is a poor prognostic factor in Acute Myeloid Leukemia (AML). 29
VALIDATION OF AN INFECTION RISK SYSTEM IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE IDELALISIB-RITUXIMAB REGIMEN 29
A REAL-LIFE STUDY OF DARATUMUMAB-BORTEZOMIB-DEX- AMETHASONE (DVD) IN LENALIDOMIDE EXPOSED/REFRAC- TORY MULTIPLE MYELOMA PATIENTS: A REPORT FROM THE MYELOMA TRIVENETO WORKING GROUP 29
The presentation of a possible effect induced by human contact with a source of high voltage electrical current 28
Subacute combined degeneration 28
OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYM- PHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY 27
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL) 27
DIFFERENT MICROENVIRONMENTAL PATTERNS OF T-CELL INFILTRATION CAN IDENTIFY MANTLE CELL LYMPHOMA PATIENTS WITH DISTINCT CLINICAL OUTCOMES. RESULTS FROM A PILOT CLINICAL-PATHOLOGICAL STUDY 27
Squamous cell carcinoma of the penis: a case report 27
Preoperative visualisation of Adamkiewicz artery by computed tomography in a patient with aortic aneurysm 27
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 26
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 23
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 23
Extensive NGS analysis in untreated CLL patients: clinical and biological correlations 23
COMPARISON OF EEG-FMRI DATA TO INVASIVE ELECTROPHYSIOLOGICAL REGISTRATION IN CRYPTOGENIC FOCAL EPILEPSY 21
Peritoneal spreading of uterine leiomyosarcoma 21
Totale 5.368
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.383
article - articoli 9.721
book - libri 0
conference - conferenze 3.126
curatela - curatele 0
other - altro 1.536
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.766
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202129 0 0 0 0 0 7 2 1 1 2 4 12
2021/202279 2 19 0 5 11 5 0 4 3 3 6 21
2022/2023265 10 31 23 43 23 70 0 25 23 1 9 7
2023/2024192 7 6 10 18 26 29 12 17 11 17 28 11
2024/2025636 21 30 48 93 29 23 39 63 74 38 64 114
2025/20264.324 83 137 129 779 2.707 489 0 0 0 0 0 0
Totale 5.595